Thermo Fisher (Thermo Fisher Scientific Inc.) reported FY 2025 revenue of USD 44.6 billion (up 4.0%), with organic revenue growth of 2.0%. GAAP operating income was USD 7.7 billion (up 6.0%), with a GAAP operating margin of 17.4 (up 0.3 pt). Adjusted operating income was USD 10.1 billion (up 4.0%) and adjusted operating margin was 22.7 (up 0.1 pt). GAAP diluted EPS was USD 17.74 (up 7.0%) and adjusted EPS was USD 22.87 (up 5.0%). Free cash flow was USD 6.3 billion. By segment in FY 2025, revenue was USD 24.0 billion for Laboratory Products and Biopharma Services (up 4.0%; 3.0% organic), USD 10.4 billion for Life Sciences Solutions (up 8.0%; 3.0% organic), USD 7.6 billion for Analytical Instruments (up 1.0%; organic flat), and USD 4.7 billion for Specialty Diagnostics (up 4.0%; 2.0% organic). Thermo Fisher said FY 2025 growth in the pharma and biotech market was partially offset by reduced demand for COVID-19 vaccine and therapy-related products and services, while academic and government revenue declined amid U.S. uncertainty and macro conditions in China; sales rose in North America, Europe and Asia-Pacific but fell in China. Corporate updates included the July 2024 acquisition of Olink Holding AB (publ) in next-generation proteomics and the September 2025 acquisition of a filtration and separation business from Solventum Corporation to strengthen bioproduction and expand industrial filtration and membrane solutions. Thermo Fisher also reported FY 2025 net interest expense of USD 426 million and a GAAP tax rate of 7.5%. In capital returns, it repurchased USD 3.0 billion of shares in FY 2025 and paid USD 0.64 billion in dividends; the board authorized a new USD 5.0 billion buyback program on Nov. 6, 2025, and the company repurchased USD 3.0 billion early in Q1 2026, leaving USD 2.0 billion available as of Feb. 26, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000097745-26-000018), on February 26, 2026, and is solely responsible for the information contained therein.
Comments